This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound
-
Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma
-
AI-driven discovery of GPNMB CAR T cells as a multi-cancer therapy
Daniel Baker, et al.. Cell, 2026.
DOI: 10.1016/j.cell.2026.06.002
Weekly News Brief: August 3–7, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of August 3–7, 2026.
This week’s brief covers FDA clearance of an AI breast ultrasound tool that improves lesion detection accuracy and cuts radiologist reading time, Fast Track designation for an AI-designed pan-TEAD inhibitor in pretreated malignant pleural mesothelioma, and an LLM-guided framework that nominated GPNMB as a promising multicancer CAR T-cell target.
To learn more about DeepHealth Breast Ultrasound, read "FDA Clears DeepHealth Breast Ultrasound for Automated Lesion Detection and Reporting," or see the press release.
For more information on ISM6331, read "AI-Designed Pan-TEAD Inhibitor Receives FDA Fast Track Designation for Mesothelioma," or see the press release.
To learn more about LLM-based CAR T-cell target discovery, read "LLM Framework Nominates GPNMB as a Multicancer CAR T-Cell Target," or see the source report in Cell.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.